Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
about
Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG studyBreast cancer medications and vision: effects of treatments for early-stage disease.The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activationCombined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.Regulation of adipose oestrogen output by mechanical stress.Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
P2860
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Switching from tamoxifen to ar ...... ents with early breast cancer.
@en
Switching from tamoxifen to ar ...... ents with early breast cancer.
@nl
type
label
Switching from tamoxifen to ar ...... ents with early breast cancer.
@en
Switching from tamoxifen to ar ...... ents with early breast cancer.
@nl
prefLabel
Switching from tamoxifen to ar ...... ents with early breast cancer.
@en
Switching from tamoxifen to ar ...... ents with early breast cancer.
@nl
P2093
P1476
Switching from tamoxifen to ar ...... ients with early breast cancer
@en
P2093
C J H van de Velde
C Masterman
J G H van Nes
P356
10.1016/J.CTRV.2009.10.003
P577
2009-11-26T00:00:00Z